# OnCo record rhabdomyosarcoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/rhabdomyosarcoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "rhabdomyosarcoma" ;
  schema:name "Rhabdomyosarcoma"@en ;
  schema:description "A childhood soft-tissue sarcoma, a cancer of muscle-like cells found anywhere from the eye socket to the bladder. Most children are cured with chemotherapy, surgery and radiation, and a fusion gene (PAX-FOXO1) now decides how intensively to treat."@en ;
  schema:url <https://onco.cc/cancers/rhabdomyosarcoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Rhabdomyosarcoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1898141> ;
  schema:citation <https://www.cancer.gov/types/soft-tissue-sarcoma/patient/rhabdomyosarcoma-treatment-pdq>, <https://doi.org/10.1016/S1470-2045(19)30617-5>, <https://clinicaltrials.gov/study/NCT04625907> ;
  onco:tag "gap-fill", "paediatric", "sarcoma" ;
  onco:related <https://onco.cc/cancers/ewing-sarcoma/>, <https://onco.cc/cancers/osteosarcoma/>, <https://onco.cc/cancers/synovial-sarcoma/>, <https://onco.cc/cancers/alveolar-soft-part-sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/pet-ct/> ;
  onco:targets <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/dactinomycin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/drugs/temsirolimus/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/temozolomide/> ;
  onco:companies <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/foxo1-fusion-status/> ;
  onco:trials <https://onco.cc/trials/ccss/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bisogno-lancet-oncol/> ;
  onco:pipeline <https://onco.cc/drugs/temsirolimus/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/targets/b7h3/>, <https://onco.cc/drugs/cobolimab/> ;
  onco:standardOfCare <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/dactinomycin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/dactinomycin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/drugs/temsirolimus/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/temsirolimus/> .